Bionos Biotech Clínica
Valencia, Spain
NCT Number: NCT07111299
The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of FPHL.
This 6-month, double-blind, placebo-controlled, 1:1 randomized clinical trial investigates whether daily supplementation with Olistic Women or Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.
This study is active but is not currently recruiting participants.
Notify Me18 year–65 year
Female
Interventional
Not applicable
Valencia, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women. Target population: women aged >35. Not recommended during pregnancy or breastfeeding.
Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women. Target population: women aged 18-35. Not recommended during pregnancy or breastfeeding.
Time frame: From enrollment to the end of treatment at 180 days.
From phototrichogram on the Sagittal midline area of the scalp
Time frame: From enrollment to the end of treatment at 180 days.
Hair shedding will be assessed by collecting shed hairs during a standardized washing and combing procedure.
Olistic Research Labs S.L.
Industry
Clinical Evaluation of Hair Loss, Hair Growth, and Skin Improvement in Human Volunteers Following a Double-blind, Placebo-controlled, 1:1 Randomized Trial of 'Olistic Next Women'
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07347145
Early Female Pattern Hair Loss (FPHL)
Wuppertal, Barmen, Germany
View Trial DetailsNCT07300228
Early Female Pattern Hair Loss (FPHL)
Valencia, Spain
View Trial Details